9 results
10-K
2023 FY
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical trials. Product candidates
20-F
2020 FY
IMCR
Immunocore Holdings plc
25 Mar 21
Annual report (foreign)
7:01am
in clinical trials may not be indicative of results obtained when such trials are completed. There is typically an extremely high rate of attrition from
424B4
IMCR
Immunocore Holdings plc
8 Feb 21
Prospectus supplement with pricing info
8:36am
trials may not be indicative of results obtained when such trials are completed. There is typically an extremely high rate of attrition from
F-1/A
IMCR
Immunocore Holdings plc
3 Feb 21
Registration statement (foreign) (amended)
5:22pm
success in clinical trials may not be indicative of results obtained when such trials are completed. There is typically an extremely high rate of attrition
F-1/A
6cl34
1 Feb 21
Registration statement (foreign) (amended)
6:21am
F-1
om1chdga76uab9xzj
15 Jan 21
Registration statement (foreign)
4:57pm
DRS/A
4cza3h2h98c70
19 Nov 20
Draft registration statement (amended)
12:00am
DRS
ccz 0tzud3
17 Nov 20
Draft registration statement
12:00am
- Prev
- 1
- Next